Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › California › Los Angeles
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Los Angeles, CA keessatti
Qorannoo 8 Luukemiya Limfoositiikii Keessummaa f Los Angeles fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente Los Angeles Medical Center, Los Angeles
- Kaiser Permanente West Los Angeles, Los Angeles
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Namoota walitti qabaa jiraSadarkaa 3
- UCLA Department of Medicine Hematologyoncology, Los Angeles
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Namoota walitti qabaa jiraSadarkaa 3
- UCLA Department of Medicine Hematologyoncology, Los Angeles
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Namoota walitti qabaa jiraSadarkaa 2
- Cedars-Sinai Medical Center, Los Angeles
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Namoota walitti qabaa jiraSadarkaa 1/2
- Valkyrie Clinical Trials, Los Angeles
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Namoota walitti qabaa jiraSadarkaa 3
- Valkyrie Clinical Trials /ID# 268151, Los Angeles
Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti
- Boston, MAQorannoo 31
- Columbus, OHQorannoo 28
- Durham, NCQorannoo 27
- Washington, DCQorannoo 22
- Seattle, WAQorannoo 20
- Rochester, MNQorannoo 18
- New York City, NYQorannoo 18
- Houston, TXQorannoo 17
- Baldwin Park, CAQorannoo 16
- Milwaukee, WIQorannoo 15
- Chicago, ILQorannoo 14
- Cincinnati, OHQorannoo 14
Qorannoo biroo Los Angeles keessatti
- Kansara Qara'a Non-Small CellQorannoo 87
- Saree (Gosoota Hunda)Qorannoo 74
- Saree OljooQorannoo 73
- Kansarii ProstateQorannoo 61
- Kansarii ColorectalQorannoo 59
- Kansara MetastatikiiQorannoo 57
- Kansarii OvariiQorannoo 50
- Dhibee QaraQorannoo 45
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 42
- Kansarii PancreasQorannoo 35
- Kansa EndometiriyaaliiQorannoo 34
- MelanomaQorannoo 34
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.